AbbVie Inc. (NYSE:ABBV) and TherapeuticsMD, Inc. (NYSE:TXMD) are both Healthcare companies that recently hit new highs. The recent price action of these companies has left many investors wondering what actions to take. To determine if one is a better investment than the other, we will compare the two names across various metrics, including growth, profitability, risk, return, dividends, and valuation.AbbVie Inc. (NYSE:ABBV) operates in the Drug Manufacturers – Major segment of the Healthcare sector. The company has grown sales at a 8.00% annual rate over the past five years, putting it in the medium growth category. ABBV has a net profit margin of 24.40% and is more profitable than the average company in the Drug Manufacturers – Major industry. In terms of efficiency, ABBV has an asset turnover ratio of 0.4. This figure represents the amount of revenue a company generates per dollar of assets. ABBV’s financial leverage ratio is 9.29, which indicates that the company’s asset base is primarily funded by debt. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 119.10%, which is better than the Drug Manufacturers – Major industry average ROE.AbbVie Inc. (ABBV) pays out an annual dividend of 2.84 per share. At the current valuation, this equates to a dividend yield of 2.98%. The company has a payout ratio of 59.90%. ABBV’s current dividend therefore should be sustainable. Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is 1.38. All else equal, companies with higher FCF yields are viewed as cheaper. Company trades at a P/E ratio of 23.06, and is less expensive than the average stock in the Drug Manufacturers – Major industry. The average investment recommendation for ABBV, taken from a group of Wall Street Analysts, is 2.30, or a buy.Over the past three months, AbbVie Inc. insiders have been net buyers, dumping a net of -276,563 shares. This implies that insiders have been feeling relatively bearish about the outlook for ABBV. Insider activity and sentiment signals are important to monitor because they can shed light on how “risky” a stock is perceived to be at it’s current valuation. Knowing this, it makes sense to look at beta, a measure of market risk. ABBV has a beta of 1.52 and therefore an above average level of market volatility.
     (adsbygoogle = window.adsbygoogle || []).push({});
TherapeuticsMD, Inc. (NASDAQ:TXMD) operates in the Drug Manufacturers – Major segment of the Healthcare sector. TXMD’s asset turnover ratio is 0.13 and the company has financial leverage of 0.07. TXMD’s return on equity of -65.20% is worse than the Drug Manufacturers – Major industry average.The average analyst recommendation for TXMD is 1.90, or a buy.TherapeuticsMD, Inc. insiders have bought a net of 5,000 shares during the past three months, which implies that the company’s top executives have been feeling bullish about the stock’s outlook. Finally, TXMD’s beta of 0.92 indicates that the stock has an above average level of market risk.AbbVie Inc. (NASDAQ:TXMD) scores higher than TherapeuticsMD, Inc. (NYSE:ABBV) on 7 of the 13 measures compared between the two companies. TXMD has the better fundamentals, scoring higher on growth and leverage metrics. TXMD has better insider activity and sentiment signals.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.